Overview

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

Status:
Active, not recruiting

Trial end date:
2037-12-15

Target enrollment:

Participant gender:

Summary

This phase I trial studies the side effects and best dose of BCMA CAR-T cells in treating patients with BCMA positive multiple myeloma that has come back or does not respond to treatment. T cells are a type of white blood cell and a major component of the immune system. T-cells that have been genetically modified in the laboratory express BCMA and may kill cancer cells with the protein BCMA on their surface. Giving chemotherapy before BCMA CAR-T cells may reduce the amount of disease and to cause a low lymphocyte (white blood cell) count in the blood, which may help the infused BCMA CAR-T cells survive and expand.

Phase:

Phase 1

Details

Lead Sponsor:

Fred Hutchinson Cancer Research Center

Collaborators:

Juno Therapeutics, Inc.
National Cancer Institute (NCI)

Treatments:

Cyclophosphamide
Fludarabine
Fludarabine phosphate